[Skip to Content]
[Skip to Content Landing]
Views 588
Citations 0
Editorial
July 2016

Improving Prostate Cancer Screening and DiagnosisHealth Policy and Biomarkers Beyond PSA

Author Affiliations
  • 1James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland
JAMA Oncol. 2016;2(7):867-868. doi:10.1001/jamaoncol.2016.0170

The initial goal of prostate cancer screening with prostate-specific antigen (PSA) was to identify men with early-stage disease according to the general oncologic principle of secondary prevention that early diagnosis and treatment would prevent disease progression and improve survival. However, 2 randomized clinical trials evaluating PSA screening and a large body of literature have identified unintended harms of overdiagnosis and overtreatment of potentially indolent prostate cancer.1,2 The revised US Preventive Services Task Force grade D recommendation for PSA screening in 2012, stating that there is a lack of evidence that its benefits outweigh its harms, further thrust prostate cancer screening into the spotlight of health policy in the United States.3

First Page Preview View Large
First page PDF preview
First page PDF preview
×